To study the effect of Bhunimba sharkra vati in vomiting in pregnancy

An Open labeled single armed clinical study of bhunimba sharkra vati in garbhini chhardi.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/03/018309

Enrollment

Registered

2019-03-29

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O211- Hyperemesis gravidarum with metabolic disturbance

Interventions

Intervention1: Bhunimba sharkra vati: Dose 500 mg 1 tds Intervention2: Bhunimba sharkra vati: 500mg tablet 1 three times a day Control Intervention1: Not applicable: Not applicable

Eligibility

Inclusion criteria

Inclusion criteria: All garbhini patient with sign and symptoms of chhardi irrespective of age, parity Garbhini chhardi with gestational age of 8-14 weeks having vomiting

Exclusion criteria

Exclusion criteria: Multiple pregnancy Vesicular mole Haemorrhagic disorders Vomiting due to other reasons such as intestinal obstruction.,cholecyststis, uraemia,hypertension, GDM, K/C/O DM

Design outcomes

Primary

Measure	Time frame
To study the effect of Bhunimba sharkra vati in garbhini chhardiTimepoint: 45 days	—

Secondary

Measure	Time frame
To study the side effects of bhunimba sharkra vati in garbhini chhardiTimepoint: 45days	—

Countries

India

Contacts

Public ContactBharati Zunjarrao

Maharashtra arogya mandala sanchalit

mandaghorpde@yahoo.com9822007570

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026